NCT05472623View on ClinicalTrials.gov

Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 21, 2023

Primary Completion Date

June 1, 2025

Study Completion Date

September 1, 2025

Conditions
Resectable Non-Small Cell Lung Cancer
Interventions
DRUG

Adagrasib

Oral Adagrasib 600 mg twice daily for 6 weeks prior to surgery.

COMBINATION_PRODUCT

Adagrasib/Nivolumab

Oral Adagrasib 400 mg twice daily for 6 weeks and IV nivolumab 240mg every 2 weeks for 3 doses prior to surgery.

Trial Locations (1)

21231

Johns Hopkins, Baltimore

Sponsors
All Listed Sponsors
collaborator

Mirati Therapeutics Inc.

INDUSTRY

collaborator

Bristol-Myers Squibb

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT05472623 - Neoadjuvant KRAS G12C Directed Therapy With Adagrasib (MRTX849) With or Without Nivolumab | Biotech Hunter | Biotech Hunter